Navigation Links
Bio-Identical Hormone Menopause Doctor Responds to Recent FDA News About Estriol
Date:1/16/2008

Cheryle R. Hart, M.D. Clarifies Previous Statement on 1/11/08

SPOKANE, Wash., Jan. 16 /PRNewswire/ -- On January 9, 2008 the FDA raised the issue regarding the use of estriol in compounded hormone replacement therapy. While awaiting further clarification, Dr. Hart suspended prescribing estriol in her medical practice. Cheryle Hart, M.D. is Mayo Clinic trained and Board certified in Ob/Gyn and founded what is now Hormones by Hart in 1997. She is also the medical director of Hormones by Hart.

Dr. Hart has been discussing this issue with medical experts in hormone replacement therapy and with some of the most experienced compounding pharmacies across the U.S. "I have learned that compounded hormone prescriptions containing estriol have been and continue to be prescribed as an important part of Hormone Replacement Therapy (HRT) throughout the United States," says Dr. Hart. The continuation of such compounding remains the subject of a major dispute between compounding pharmacies and the FDA.

The International Academy of Compounding Pharmacists (IACP) -- who represents thousands of compounding pharmacies -- says that the situation with estriol is comparable to many commonly prescribed drugs. While estriol was never formally approved by the FDA, it has a monograph from the U.S. Pharmacopeia (USP) prior to 1997. When Congress passed the FDA Modernization Act in 1997, Congress clearly indicated that drugs with a USP monograph could still be compounded when prescribed by a licensed medical practitioner.

"With this new information and clarification from the IACP, I am updating my previous intentions about prescribing compounds containing estriol," says Dr. Hart. "Until the courts give us the final word on this subject, I will continue to prescribe estriol as an important part of the total hormone replacement therapy for my patients -- whom I have found to benefit from its use. I want my patients to know that all of their prescription hormones are still going to be available," promises Cheryle R. Hart, M.D.

If you would like to let the FDA know how you feel, please go to their comment website at: http://www.fda.gov/cder/comment.htm

IACP Reply to FDA News on BHRT: http://www.iacprx.org/

Statement From The American Pharmacists Association Regarding FDA's Action http://www.medicalnewstoday.com/articles/93953.php

Original FDA News Release January 9, 2008: http://www.fda.gov/bbs/topics/NEWS/2008/NEW01772.html


'/>"/>
SOURCE Cheryle R. Hart, M.D.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bio-Identical Hormone Menopause Doctor Responds to Outrageous FDA News
2. Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device
3. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
4. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
5. Medical Breakthrough ... Doctor Discovers Penetrating Carrier That Eradicates Fungus
6. Patient Treatment for Bipolar Disorder Varies Depending on Doctor Specialty; Well Designed Clinical Trials May Be The Answer
7. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
8. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
9. Michigan Catholic Conference Responds to Formation of Embryonic Stem Cell Research Ballot Committee
10. Updated Drug Development Scrip Report Responds to the Pharma Industrys Major Changes
11. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 11, 2017  VMS BioMarketing, a leading provider of patient ... Clinical Nurse Educator (CNE) network, which will launch this week. ... among health care professionals to enhance the patient care experience ... and other health care professionals to help women who have ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published ... frozen and fresh in vitro fertilization (IVF) transfer cycles. The multi-center ... success. , After comparing the results from the fresh and frozen transfer cohorts, ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... DALLAS , Oct. 10, 2017 International research firm ... IoT Strategy, will speak at the TMA 2017 Annual Meeting , ... key trends in the residential home security market and how smart safety ... ... "The ...
Breaking Biology Technology:
(Date:6/14/2017)... PARIS , June 15, 2017  IBM (NYSE: IBM ... the international tech event dedicated to developing collaboration between startups ... on June 15-17. During the event, nine startups will ... deliver value in various industries. ... in the international market, with a 30 percent increase in ...
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):